Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Business Journal.
Press releases published on May 5, 2025
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …
As Federal Collections Activity Resumes, More Than One in Five Federal Student Loan Borrowers With a Payment Due are Seriously Delinquent
GlobeNewswire
·
May 5, 2025
CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- As the U.S. Department of Education begins resuming collections activities among defaulted borrowers, new research reveals that the number of consumers at risk for default has soared past pre-pandemic levels. These …
Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
GlobeNewswire
·
May 5, 2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- IGI, Inc., a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track …
IRADIMED CORPORATION Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in …
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
GlobeNewswire
·
May 5, 2025
WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
GlobeNewswire
·
May 5, 2025
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across …
Colliers adds leading telecommunications engineering firm
GlobeNewswire
·
May 5, 2025
TORONTO and CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today that its Colliers Engineering …
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
May 5, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced …
EnviroGold Global Announces Appointment of Paul McRae as Non-Executive Chair
GlobeNewswire
·
May 5, 2025
TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a clean technology company unlocking significant value from mine waste and tailings while promoting environmental …
Apollo Silver Appoints Ross McElroy as President and CEO
GlobeNewswire
·
May 5, 2025
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce the appointment of Mr. Ross McElroy as President and CEO, effective immediately, …
PLBY Group to Report First Quarter 2025 Financial Results on May 15, 2025
GlobeNewswire
·
May 5, 2025
LOS ANGELES, May 05, 2025 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, will report …
GXO and Blue Yonder Announce New Strategic Global Agreement
GlobeNewswire
·
May 5, 2025
New agreement creates strategic growth opportunities for both companies while delivering industry-leading supply chain solutions for customers GREENWICH, Conn. and DALLAS, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world’s …
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
GlobeNewswire
·
May 5, 2025
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, …
Algorhythm Holdings Acquires SemiCab India, Expands Global AI Transportation Footprint
GlobeNewswire
·
May 5, 2025
Acquisition Adds Multiple Multinational Customers in India and Unlocks Scalable Growth Opportunities in Rapidly Growing Indian Market Fort Lauderdale, FL, May 05, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME), a …
AAFA Calls on Congress to Restore Lifesaving National Asthma Control Program
GlobeNewswire
·
May 5, 2025
Washington, DC, May 05, 2025 (GLOBE NEWSWIRE) -- On May 6, 2025 – World Asthma Day – the Asthma and Allergy Foundation of America (AAFA) will visit the U.S. Capitol to call on Congress to protect the 28 million people in the U.S. with asthma and restore …
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
GlobeNewswire
·
May 5, 2025
Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months active drug continued to be released into the esophagus in …
Osisko Metals Intersects 323 Metres Averaging 0.43% Cu at Gaspé Project
GlobeNewswire
·
May 5, 2025
MONTREAL, May 05, 2025 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company or "Osisko Metals") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce new drilling results from the 2025 drilling program at the Gaspé Copper Project, …
MTY Food Group Inc. Announces Results from 2025 Annual General Meeting
GlobeNewswire
·
May 5, 2025
MONTREAL, May 05, 2025 (GLOBE NEWSWIRE) -- MTY Food Group Inc. (“MTY” or the “Company”) (TSX: MTY), franchisor and operator of multiple concepts of restaurants, is pleased to report the results from the votes from its shareholders for the 2025 Annual …
Métaux Osisko recoupe 323 mètres à une teneur moyenne de 0,43 % cuivre à Mines Gaspé
GlobeNewswire
·
May 5, 2025
MONTRÉAL, 05 mai 2025 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (la « Société » ou « Métaux Osisko ») (TSXV : OM; OTCQX : OMZNF; FRANKFURT : 0B51) a le plaisir d’annoncer de nouveaux résultats de forage issus du programme de forage 2025 sur le projet …
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
GlobeNewswire
·
May 5, 2025
NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the “ …